Prix Iris for Most Successful Film Outside Quebec

Contentstack Unveils First-Ever Composable Charter and Announces Contentstack Excellence Award Winners at ContentCon 2023

Retrieved on: 
Wednesday, May 10, 2023
Icelandair, Travel, DXP, Integration, API, Sky Group, BigCommerce, PostNL, Automation, EPAM, Reuters - The World's Most Innovative Universities, Movement, Publishing, Software, Partner, Digital transformation, Prix Iris for Most Successful Film Outside Quebec, Digital asset management, A Composer's Guide to Game Music, Metrolinx, Management, Video game, ASICS, Aprimo

AUSTIN, Texas, May 10, 2023 /PRNewswire/ -- Contentstack, the composable digital experience platform (DXP) category leader and pioneer, today announced the creation of the first-ever Composable Charter by more than 100 of Contentstack's customers and partners who are industry leaders across retail, travel, technology, and more. Brands and partners including, but not limited to, ASICS, Metrolinx, Brad's Deals, PostNL, Aprimo, EPAM, and BigCommerce participated in the creation of the charter at ContentCon 2023, Contentstack's annual thought leadership event.

Key Points: 
  • The Composable Charter provides a framework of 10 guiding principles applicable to enterprises across all industries seeking to future-proof their business through the adoption of composable technologies and architectures.
  • Contentstack also announced the winners of the 2023 Contentstack Experience Awards to recognize customer and partner leaders.
  • Aprimo for Partner of the Year – partnered with Contentstack on the "Composable Heroes" project, Automation Hub, and Aprimo's Digital Asset Management.
  • Over the course of the event, Contentstack announced a series of initiatives to help brands accelerate their composable digital experiences, including the Composable Charter, the General Availability of Contentstack Launch, a Go Composable resource site, and the new Contentstack Academy.

Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research

Retrieved on: 
Friday, September 24, 2021
MSD, RATS, Safety, Clinical trial, Vaccine, PK, Accreditation, GLP, BD, LC-MS/MS, Biomarker, Cell biology, Prix Iris for Most Successful Film Outside Quebec, Toxicology, Flow cytometry, Industry, Dog, Program, Severe acute respiratory syndrome coronavirus, Immunology, Trial of the century, COVID-19, PD, Severe acute respiratory syndrome coronavirus 2, Research, Tran, NATA, A3, Laboratory, Mesoscale, OECD, Chappell, Tapley, Fine chemical, Pharmaceutical industry, Television

Agilex Biolabs offers advanced bioanalytical services for biotech companies and delivers toxicology services to support pre-clinical and early phase research within their TetraQ, division.

Key Points: 
  • Agilex Biolabs offers advanced bioanalytical services for biotech companies and delivers toxicology services to support pre-clinical and early phase research within their TetraQ, division.
  • Dr. Peter Tapley, Director Toxicology at TetraQ, said the research submitted for the Citeline Award focussed on preclinical assessment of the safety and tolerability of a SARS-CoV-2 Sclamp protein subunit COVID-19 vaccine in rats.
  • "This research highlights the pathways that biotech companies can take for rapid vaccine development, and how the Australian research, regulatory and clinical infrastructure provides a supportive environment."
  • Agilex Biolabs also offers toxicology services through TetraQ an Agilex Biolabs company, an established GLP toxicology facility in Australia.

Neumentum and NEMA Research Inc. Named to Short-List of Citeline Awards for 2021

Retrieved on: 
Monday, September 20, 2021
Vomiting, Prescription, Pain, Somnolence, Chronic pain, Research, Pain management, Johnson & Johnson, Tris, NEMA, Constipation, Company, Nausea, Family, Prix Iris for Most Successful Film Outside Quebec, Toxicology, CEO, Program, Neurology, Drug development, NSAID, Safety, Doctor of Philosophy, Plasma, GLOBE, Pharmaceutical industry

MORRISTOWN, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- The Citeline Awards, sponsored by Informa Pharma Intelligence, today announced that Neumentum Inc. and NEMA Research, Inc., have been nominated and are in consideration for an award this year for Most Successful Early-Phase Research Company. Neumentum is pioneering the development of a powerful, effective nonopioid analgesic agent for use to control postoperative pain. This early-phase research study was designed to test the safety and toxicology of a 48-hour continuous infusion regimen of ketorolac tromethamine (NTM-001) which is intended to provide stable plasma levels of ketorolac rather than the peaks and troughs of bolus dosing. This 48-hour continuous infusion regimen is groundbreaking, and the study successfully demonstrated its safety and toxicology.

Key Points: 
  • MORRISTOWN, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- The Citeline Awards, sponsored by Informa Pharma Intelligence, today announced that Neumentum Inc. and NEMA Research, Inc., have been nominated and are in consideration for an award this year for Most Successful Early-Phase Research Company.
  • Neumentum is developing a novel continuous infusion of ketorolac tromethamine, NTM-001, to address these limitations associated with the bolus regimen.
  • Citeline Awards are given every year to honor large and small clinical research organizations for outstanding work.
  • NEMA Research is a clinical research organization headquartered in Naples, Florida.